South Korean court halts KRX delisting decision against KM Pharmaceutical pending main lawsuit

• Seoul Southern District Court ordered a suspension of the Korea Exchange’s Sept. 14 delisting decision on KMPharmaceutical shares.
• The injunction remains in effect until a final ruling in the main lawsuit, blocking the exchange from starting the liquidation trading process.
• The court decision was confirmed on Oct. 2, 2026; the outcome could change depending on the main case or appeal steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KMPharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002901024), on October 02, 2026, and is solely responsible for the information contained therein.